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Abstract
Background and purpose If patients presenting with large vessel occlusions (LVO) and mild symptoms should be treated 
with endvoascular treatment (EVT) remains unclear. Aims of this study were (1) assessing the safety and technical efficacy 
of EVT in patients with NIHSS < 8 as opposed to a comparison group of patients presenting with NIHSS ≥ 8 and (2) evalu-
ation of the clinical effect of reperfusion in patients with NIHSS < 8.
Methods Patients included into the retrospective multicenter BEYOND-SWIFT registry (NCT03496064) were analyzed. 
Clinical effect of achieving successful reperfusion (defined as modified Thrombolysis in Cerebral Infarction grade 2b/3) 
in patients presenting with NIHSS < 8 (N = 193) was evaluated using multivariable logistic regression analyses (displayed 
as adjusted Odds Ratios, aOR and 95% confidence intervals, 95%-CI). Primary outcome was excellent functional outcome 
(modified Rankin Scale, mRS 0–1) at day 90. Safety and efficacy of mechanical thrombectomy in patients with NIHSS < 8 
was compared to patients presenting with NIHSS ≥ 8 (N = 1423).
Results Among patients with NIHSS < 8 (N = 193, 77/193, 39.9% receiving pre-interventional IV-tPA), successful reperfu-
sion was significantly related to mRS 0–1 (aOR 3.217, 95%-CI 1.174–8.816) and reduced the chances of non-hemorrhagic 
neurological worsening (aOR 0.194, 95%-CI 0.050–0.756) after adjusting for prespecified confounders. In interaction 
analyses, the relative merits of achieving successful reperfusion were mostly comparable between patients presenting with 
NIHSS < 8 and NIHSS ≥ 8 as evidenced by non-significantly different aOR. Interventional safety and efficacy metrics were 
similar between patients with NIHSS < 8 and NIHSS ≥ 8.
Conclusions Achieving successful reperfusion is beneficial in patients with persisting LVO presenting with NIHSS < 8 and 
reduces the risk of non-hemorrhagic neurological worsening.
Keywords Mild symptoms · Mechanical thrombectomy · Endovascular · Low NIHSS · Thrombolysis · Stroke
Introduction
In a considerable proportion of stroke patients presenting 
with mild neurological symptoms, a proximal anterior cir-
culation large-vessel occlusion (LVO) is identified as the 
underlying cause [1, 2]. However, in most patients with 
proximal LVO and low NIHSS scores on admission, indica-
tions for endovascular treatment (EVT) are not covered by 
current evidence derived from the large pivotal thrombec-
tomy trials [3, 4]. In these patients, a well-developed col-
lateral network presumably ensures sufficient blood flow to 
the territory distal to the occlusion site and neuronal func-
tioning is largely maintained [5]. Intravenous thrombolysis 
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(IVT) is the standard of care in patients presenting with mild 
disabling symptoms [6]. However, in patients with proxi-
mal LVO, IVT is often insufficient to recanalyze large clots 
and some patients deteriorate clinically [7–9] and tend to 
have poor outcomes if no reperfusion therapy is attempted, 
accordingly [10–12]. Hence, one of the most relevant unan-
swered questions is currently whether immediate EVT in 
patients with mild symptoms and LVO should be routinely 
considered to prevent clinical deterioration and to reduce 
infarct growth [11, 13–19]. While a proportion of patients 
will most likely benefit from routine EVT by preventing 
infarct growth, EVT also harbors the risk of worsening cer-
ebral perfusion by thrombus dislocation and subsequent col-
lateral shutdown and other procedural complications [20] 
(e.g. dissection [21], perforation [22], infarct to new territory 
[23], etc.).
The main aims of this registry analysis were (1) to assess 
safety and technical efficacy of EVT in LVO patients with 
NIHSS < 8 when opposed to a large comparison group of 
patients with severe symptoms and (2) to evaluate the clini-
cal effect of timely blood flow restoration in patients with 
NIHSS < 8 as evidenced by measures of angiographical rep-
erfusion success.
Methods
BEYOND‑SWIFT registry
The Bernese–European RegistrY for ischemic stroke patients 
treated Outside current guidelines with Neurothrombectomy 
Devices using the SOLITAIRE™ FR With the Intention 
For Thrombectomy (BEYOND-SWIFT) is a retrospective, 
international, multicenter observational registry (https ://
clini caltr ials.gov/ct2/show/NCT03 49606 4). Inclusion cri-
teria were (1) Treatment with a Medtronic market-released 
neurothrombectomy device (applied as initial devices used 
for intervention) in acute ischemic stroke patients. Patients 
were treated at the discretion of the investigator, independ-
ent of participation in this registry; (2) Patients or patient’s 
legally authorized representatives have given informed con-
sent according to Good Clinical Practices (GCP) and/or IRB 
and/or local or institutional policies allow use of observa-
tional registry data for research purposes.
Patients were excluded if they participated in another 
clinical trial or had withdrawn their consent for retrospective 
analyses. The following centers participated and contributed 
data of consecutive patients admitted to their hospital:
• Inselspital Bern, University Hospital Bern, University of 
Bern, Bern, Switzerland.
• CHUV, Lausanne University Hospital, Lausanne, Swit-
zerland.
• Klinikum rechts der Isar, Technical University Munich, 
Munich, Germany.
• Montpellier CHU, University Hospital Montpellier, 
Montpellier, France.
• CHU Reims, University Hospital Reims, Reims, France.
• University Hospital Vall d’Hebron, Barcelona, Spain.
• Toronto Western Hospital—University Health Network, 
University of Toronto, Toronto, Canada.
An overview of included patients and rates of available 
follow-up data for each center can be found in Supplemen-
tary Table I. Ethical approval for inclusion of patient data 
in this pooled registry was obtained at each local responsi-
ble ethics committee (see Supplementary Table I). Addi-
tionally, ethical approval was obtained in Bern for pooling 
and anonymized analyses of the registry data (KEK Bern, 
Bern, Switzerland, Local Ethics Committee Study Identifier: 
2018-00766).
Most patients included in the BEYOND-SWIFT 
(n = 2046) registry were treated for large-vessel anterior cir-
culation strokes (n = 1820). Of these, 1630 had documented 
90-day follow-up including 1616 with records of admission 
NIHSS. One-hundred-ninety-three of these patients pre-
sented with NIHSS < 8 (11.9%, see Fig. 1 for study flow-
chart). The corresponding lost-to-follow-up rate in the sub-
group of patients with NIHSS < 8 was 6.3% (13/206).
Variables and image analysis
The site of occlusion was categorized by local investiga-
tors into intracranial internal carotid artery, carotid-T/L, 
first/second/third segment of the middle cerebral artery 
(M1/M2/M3), first/second segment of the anterior cerebral 
artery (A1/A2), vertebral artery, basilar artery, or first/sec-
ond segment of the posterior cerebral artery (P1/P2). For 
7 patients, no data on occlusion site was available. Post-
interventional modified thrombolysis in cerebral infarc-
tion (mTICI, 50% or more reperfusion defined as TICI2b) 
scale was operator adjudicated at each center or rated by 
an independent research fellow, depending on the standard 
of the respective centers (see Supplementary Table I) [24]. 
Anterior circulation extracranial–intracranial tandem occlu-
sion were defined as the presence of an intracranial LVO 
and > 90% cervical stenosis or occlusion. Of 1616 patients 
with anterior circulation LVO strokes, records of admission 
NIHSS and day 90 follow-up,  974 (60.3%) underwent CT 
for admission workup, while 609 (37.7%) patients received 
magnetic resonance imaging (MRI) including diffusion-
weighted sequences. For 33 patients  (2.0%) no information 
on admission imaging modality was provided. ASPECTS 
was evaluated at each site (see Supplementary Table  I) 
and   scores were available for 1518/1616  (93.9%) patients 
in the whole cohort and in 184/193 (95.3%) patients with 
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NIHSS<8 (including one patient with available ASPECTS 
but missing data on admission imaging modality). For clini-
cal outcome evaluation, 3-month functional outcome was 
assessed applying the modified Rankin Scale (mRS) in rou-
tinely scheduled clinical visits or standardized telephone 
interviews, organized at each center. Rates of symptomatic 
intracerebral hemorrhage were reported by each center using 
the ECASS-II definition.
Statistical analysis
The primary endpoint of this analysis was mRS 0–1 
(excellent outcome) at day 90. Secondary and safety out-
comes consisted of mRS 0–2 (good outcome) at day 90, 
all-cause mortality at day 90, non-hemorrhagic neurologi-
cal worsening and symptomatic intracerebral hemorrhage, 
which was assessed at each center applying the ECASS 
II criteria. Non-hemorrhagic neurological worsening was 
defined as drop in the NIHSS ≥ 4 [25] between admission 
NIHSS and 24 h NIHSS without the occurrence of sICH 
[8]. Data on 24 h NIHSS were available for 1193/1616 
in the complete cohort and 160/193 in the subcohort of 
patients with NIHSS < 8. Note that in a comparison of no 
non-hemorrhagic neurological worsening vs non-hemor-
rhagic neurological worsening, patients with sICH (N = 8) 
are excluded, leaving N = 152 patients for final analysis in 
the subcohort of patients with NIHSS <8. Confidence 
intervals of proportions were calculated using the method 
outlined by Wilson, implementing a continuity correction 
[26]. Univariate comparisons between patients in whom 
reperfusion was successful (mTICI 2b/3) and those in 
whom it was unsuccessful (mTICI ≤ 2a) were made using 
standard statistical measures (Fisher’s exact test for cate-
gorical variables, Whitney–Mann U Test for non-normally 
continuous or ordinally scaled variables and Welsch’s t test 
for independent normally distributed data). Association of 
successful reperfusion with all outcome parameters was 
assessed using multivariable logistic regression adjusting 
for the following pre-specified confounders: age (contin-
uous), sex (categorical), NIHSS on admission (ordinal, 
adjusted odds ratio (aOR) per point increase), tandem vs 
non-tandem (categorical, tandem defined as > 90% cer-
vical stenosis or cervical occlusion), center (categori-
cal, contrast type: indicator, comparator: largest center), 
adjusted ASPECTS (see below, ordinal, adjusted odds 
ratio (aOR) per point increase), intravenous thromboly-
sis (categorical), risk factor hypertension (categorical), 
risk factor dyslipidemia (categorical), risk factor smok-
ing (categorical), risk factor previous stroke (categorical), 
risk factor diabetes (categorical), in-hospital stroke (cate-
gorical), type of admission imaging (CT vs MRI, categori-
cal), intracranial ICA/carotid-T vs M1 vs M2 occlusion 
Fig. 1  Study Flow Chart of the BEYOND-SWIFT Registry
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(categorical, contrast type: indicator, comparator: ICA). 
To account for the imaging modality on admission (i.e. 
non-contrast CT vs DWI–MRI) on which the ASPECTS 
scoring was based upon, we increased all DWI–ASPECTS 
for regression analyses by 1 point according to the results 
derived from the SAMURAI registry [27]. For sensitivity 
purposes, analyses were rerun considering only patients 
with NIHSS < 6 and also after additional implementation 
of the interaction term successful reperfusion * IVT.
Results
Of the 1616 patients included into this analysis, 193 patients 
had an initial NIHSS < 8 (median NIHSS 5, IQR 4–6), com-
prising 103 patients with NIHSS < 6. Distribution of the 
NIHSS scores in treated patients with NIHSS < 8 is depicted 
in Supplementary Figure I. Patients with NIHSS < 8 had 
better outcome than patients with NIHSS ≥ 8 (N = 1423), 
as evidenced by higher rates of excellent functional out-
come (mRS 0–1, 45.1% vs 25.6%, P < 0.001, see Fig. 2a) 
and lower mortality (16.1% vs 24.9%, P = 0.007). However, 
rates of non-hemorrhagic neurological worsening tended to 
be higher in patients with NIHSS < 8 as compared to patients 
with NIHSS ≥ 8 (13.8% vs 9.0%, P = 0.076).
In patients with NIHSS < 8, there were no differences 
in baseline characteristics, comorbidities or treatment met-
rics when comparing patients with and without successful 
reperfusion (Table 1). Admission ASPECTS were not dif-
ferent between patients with successful and without suc-
cessful reperfusion (MRI-DWI: median 9 vs 8, p=0.235, 
CT: median 9 vs 9, 0.248, respectively). However, better 
outcomes were observed in patients with successful reperfu-
sion as indicated by significantly higher rates of mRS 0–1 
(49.7% vs 21.9%, P = 0.006, Fig. 2b) and mRS 0–2 (71.4% 
vs 37.5%, P < 0.001). Median NIHSS improvement at 24 h 
was 3 (IQR 0–5) in successfully reperfusion patients and 
− 3 in non-successfully reperfused patients (IQR − 11–0, 
P < 0.001, Supplementary Figure II). The overall incidence 
of non-hemorrhagic neurological worsening in patients 
without sICH was 13.8% (95%-CI 9.0%–20.6%), with sig-
nificant differences among successfully reperfused patients 
and patients without successful reperfusion (9.9% vs 38.1%, 
P = 0.002). Rates of non-hemorrhagic neurological worsen-
ing were comparable among IVT and non-IVT pretreated 
patients (12.5% vs 14.8%, P = 0.813) and the reducing effect 
successful reperfusion on non-hemorrhagic neurological 
worsening was tangible also considering strata of IVT vs 
non-IVT patients (see Supplementary Table II). There was 
a trend towards lower mortality (13.7% vs 28.1%, P = 0.062) 
and lower rates of sICH (3.1% vs 9.4%, P = 0.131) if suc-
cessful reperfusion was achieved.
Among patients with NIHSS < 8, successful reperfusion 
was a significant factor related to mRS 0–1 (aOR 3.217, 
95%-CI 1.174–8.816, Table  2), mRS 0–2 (aOR 2.995, 
95%-CI 1.140–7.868) and reduced the chances of non-
hemorrhagic neurological worsening (aOR 0.194, 95%-CI 
0.050–0.756) in multivariable binary logistic regression 
analysis adjusting for prespecified confounders outlined in 
the methods section. No significant associations were found 
for the endpoints sICH (aOR 0.086, 95%-CI 0.006–1.234) 
and day 90 mortality (aOR 0.776, 95%-CI 0.240–2.509), 
although point estimates favored reperfusion. No signifi-
cant interactions between the above-mentioned associations 
and IVT pretreatment status were observed (P for interac-
tion > 0.05, see Table 2). The point estimates remained 
significant for mRS 0–1 in a subgroup of patients with 
NIHSS < 6, although uncertainty of the point estimates 
increased considerably (see Table 3). The relative merits of 
achieving successful reperfusion for various endpoints were 
comparable between patients presenting with NIHSS < 8 
and NIHSS ≥ 8 (Fig. 3). However, reduction of mortality 
and sICH was found to be significant only in the cohort 
of patients presenting with NIHSS ≥ 8. Here, a significant 
Fig. 2  Day 90 Functional Outcome. a Comparison of patients with NIHSS < 8 and patients presenting with NIHSS ≥ 8; b, Patients with 
NIHSS < 8 dichotomized according to their reperfusion success; NIHSS National Institute of Health Stroke Scale, mRS modified Rankin Scale
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interaction regarding the mortality reducing effect of suc-
cessful reperfusion was found, suggesting the effect to be 
larger in patients presenting with NIHSS ≥ 8 (Fig. 3).
When comparing patients with NIHSS < 8 and patients 
with NIHSS ≥ 8, a tendency for shorter groin-puncture to 
reperfusion intervals in patients with NIHSS < 8 could be 
noted (median 42 min vs 47 min, P = 0.075). Apart from this, 
no differences in interventional safety and efficacy param-
eters were found (see Table 4). In particular rates of success-
ful reperfusion (83.4% vs 82.2%, P = 0.690), TICI3 reperfu-
sion (47.7% vs 44.4%, P = 0.441) and complications (11.4% 
vs 12.6%, P = 0.818) did not differ between patients present-
ing with mild symptoms and patients with NIHSS ≥ 8.
Discussion
This registry-based retrospective analysis of consecutive 
patients treated with stent-retrievers has the following main 
findings: (1) Successful reperfusion is associated with better 
functional long-term outcome and early neurologic recov-
ery in treated patients presenting with NIHSS < 8. (2) The 
Table 1  Patients with NIHSS < 8 stratified according to reperfusion success (TICI0-2a vs TICI2b/3)
NIHSS National Institute of Health Stroke Scale, TICI Thrombolysis in Cerebral Infarction, IVT intravenous thrombolysis, CVE cerebrovascular 
event, iICA intracranial ICA, TOAST Trial of ORG 10,172 in Acute Stroke Treatment, mRS modified Rankin Scale, IQR interquartile range
† P < 0.01
NIHSS < 8, N = 193 TICI0-3 (N = 193) TICI0-2a (N = 32) TICI2b/3(N = 161) P value
Age (years) 66.7 + /− 14.6 68.2 + /− 13.1 69.95 + /−14.9 0.503
Sex, female 55.4% (107/193) 53.1% (17/32) 55.9% (90/161) 0.846
Admission NIHSS 5 (IQR 4–6) 5 (IQR 3–6) 5 (IQR 4–6) 0.777
In-hospital stroke 1.6% (3) 0.0% (0/32) 1.9% (3/161) > 0.999
Transfer 36.5% (70/192) 38.7% (12/31) 36.0% (58/161) 0.839
Witnessed symptom-onset/last-seen well to admission 
(min, N = 178)
148 (IQR  
85–282)
201 (IQR 79–282, N = 29) 146 (IQR 87–285, N = 149) 0.769
Witnessed symptom-onset/last-seen well to groin punc-
ture (min, N = 162)
257 (IQR 
196–393)
295 (225–455, N = 26) 250 (195–370, N = 136) 0.248
Admission Imaging, MRI (N = 191) 57.6% (110/191) 50.0% (16/32) 59.1% (94/159) 0.433
IVT 39.9% (77/193) 31.3% (10/32) 41.6% (67/161) 0.326
Risk factors
 Smoking (N = 191) 28.8% (55/191) 18.8% (6/32) 30.8% (49/159) 0.203
 Hypertension (N = 193) 60.1% (116/193) 56.3% (18/32) 60.9% (98/161) 0.694
 Dyslipidemia (N = 192) 56.3% (108/192) 51.6% (16/31) 57.1% (92/161) 0.693
 Previous CVE (N = 191) 12.6% (24/191) 3.1% (1/32) 14.5% (23/159) 0.086
 Diabetes (N = 193) 13.5% (26/193) 21.9% (7/32) 11.8% (19/161) 0.154
Occlusion site 0.203
 iICA 2.1% (4/193) 3.1% (1/32) 1.9% (3/161)
 Carotid-T/L 6.2% (12/193) 12.5% (4/32) 5.0% (8/161)
 M1 58.5% (113/193) 46.9% (15/32) 60.9% (98/161)
 M2 33.2% (64/193) 37.5% (12/32) 32.3% (52/161)
Extracranial–intracranial tandem occlusion 15.5% (30/193) 21.9% (7/32) 14.3% (23/161) 0.290
Underlying cervical dissection 5.2% (10/193) 6.3% (2/32) 5.0% (8/161) 0.673
TOAST (N = 192) 0.242
 Large-artery 9.4% (18/192) 15.6% (5/32) 8.1% (13/160)
 Cardioembolism 41.1% (79/192) 28.1% (9/32) 43.8% (70/160)
 Other 8.9% (17/192) 12.5% (4/32) 8.1% (13/160)
 Unknown 40.6% (78/192) 43.8% (14/32) 50.0% (64/160)
Outcome
 mRS 0–1 45.1% (87/193) 21.9% (7/32) 49.7% (80/161) 0.006†
 mRS 0–2 65.8% (127/193) 37.5% (12/32) 71.4% (115/161) < 0.001†
Non-hemorrhagic neurological worsening (N = 152) 13.8% (21/152) 38.1% (8/21) 9.9% (13/131) 0.002†
Mortality 16.1% (31/193) 28.1% (9/32) 13.7% (22/161) 0.062
sICH (N = 192) 4.2% (8/192) 9.4% (3/32) 3.1% (5/160) 0.131
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effect remained tangible in the subgroup of patients with 
NIHSS < 6, however, there is large uncertainty according 
to the small sample size. (3) When compared with patients 
presenting with severe symptoms, interventional procedures 
in patients with NIHSS < 8 were equally safe and technically 
effective and the relative merit of successful reperfusion 
on promoting good outcome was comparable.
Irrespective of treatment modalities, patients with low 
NIHSS and large-vessel occlusion have a more benign 
course than their counterparts presenting with severe 
neurological deficits [28]. Several underlying factors are 
causal for this observation, including incomplete occlu-
sion [29, 30], partially permeable thrombi [31], and 
excellent collaterals, all of which allow for an adequately 
maintained blood flow to the brain tissue located distally 
to the LVO. However, there is compelling evidence that 
reperfusion therapies (IVT and/or EVT) improve the out-
come of LVO patients also if they present only with mild 
neurological symptoms [11, 32–34]. Still, around 10–30% 
of patients will deteriorate after IVT treatment, which is 
a phenomenon related to lysis-refractoriness, “collateral-
failure”[35–39] and thrombus extension [40]. Correspond-
ingly, nearly one-quarter of patients primarily treated with 
medical therapy do not achieve functional independence 
[33] and > 60% of patients without successful reperfu-
sion remained functionally depend in the presented cohort. 
As long as those patients—likely to deteriorate—cannot 
precisely be identified a priori, there are two general treat-
ment approaches, both having their advantages and dis-
advantages: (1) Subjecting all patients with acute LVO 
to EVT, thus putting patients at interventional risk, who 
would have reperfused spontaneously or after IVT treat-
ment at comparable time points; (2) Only subject patients 
to EVT if they experience clinical deterioration, implying 
that reperfusion will be achieved later and risking that 
additional tissue will undergo infarction. A recent multi-
center study comparing both of these treatment approaches 
on a center-level basis, found that patients undergoing 
either emergent mechanical EVT or delayed EVT in 
case of secondary clinical deterioration had comparable 
Table 2  Adjusted Odds ratios 
for TICI2b/3 for different 
outcome measures in patients 
with NIHSS < 8
NIHSS National Institute of Health Stroke Scale, aOR adjusted Odds Ratio, TICI Thrombolysis in Cerebral 
Infarction, 95% CI 95% confidence interval, IVT intravenous thrombolysis, mRS modified Rankin Scale, 
sICH symptomatic intracerebral hemorrhage
† P < 0.05
NIHSS < 8 N = 193 N included in 
the model
aOR TICI2b/3 95%-CI P P for interac-
tion with IVT
Primary
 mRS 0–1 179/193 3.217 1.174–8.816 0.023† 0.343
Secondary
 mRS 0–2 179/193 2.995 1.140–7.868 0.026† 0.430
 sICH 178/193 0.086 0.006–1.234 0.071 0.997
 Mortality 179/193 0.776 0.240–2.509 0.672 0.874
 Non-hemorrhagic neu-
rological worsening
142/193 0.194 0.050–0.756 0.018† 0.944
Table 3  Adjusted Odds ratios 
for TICI2b/3 for different 
outcome measures in patients 
with NIHSS < 6
NIHSS National Institute of Health Stroke Scale, aOR adjusted Odds Ratio, TICI Thrombolysis in Cerebral 
Infarction, 95% CI 95% confidence interval, IVT intravenous thrombolysis, mRS modified Rankin Scale, 
sICH symptomatic intracerebral hemorrhage
† P < 0.05
NIHSS < 6 N = 103 N included in 
the model
aOR TICI2b/3 95%-CI P P for interac-
tion with 
IVT
Primary
 mRS 0–1 98/103 4.878 1.196–19.889 0.027† 0.934
Secondary
 mRS 0–2 98/103 3.690 0.911–14.949 0.067 0.795
 sICH 97/103 Did not converge – – –
 Mortality 98/103 1.068 0.180–6.343 0.942 0.936
 Non-hemorrhagic neu-
rological worsening
77/103 0.111 0.011–1.083 0.059 0.149
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outcomes [28]. However, depending on the type of analy-
sis, a trend towards better outcome in patients undergoing 
emergent EVT was noted [28]. A similar observation was 
made in a multi-center cohort described by Haussen et al. 
Here, the authors found that mechanical thrombectomy in 
patients presenting with NIHSS ≤ 5 was associated with 
higher rates of functional independence and a favorable 
NIHSS shift when compared to medical management 
Fig. 3  adjusted Odds Ratios of successful reperfusion (TICI2b/3) for 
various endpoints with strata of admission NIHSS < 8 vs NIHSS ≥ 8. 
Adjusted Odds Ratios were calculated in split cohorts using multivar-
iable binary logistic regression adjusting for all variables outlined in 
the methods section. Analysis was rerun implementing the variable 
NIHSS < 8 vs NIHSS ≥ 8 and the term NIHSS < 8 vs NIHSS ≥ 8 * 
TICI2b/3 (reperfusion) to test for potential interaction  in the whole 
cohort (the variable admission NIHSS was ommitted in this model, 
accordingly)
Table 4  Comparison of technical efficacy and safety in patients with NIHSS < 8 compared to patients with NIHSS ≥ 8
NIHSS National Institute of Health Stroke Scale, mRS modified Rankin Scale, TICI Thrombolysis in Cerebral Infarction, ENT emboli to new ter-
ritory, sICH symptomatic intracerebral hemorrhage
All anterior circulation LVO strokes with available mRS 
and NIHSS (N = 1621)
NIHSS < 8 (N = 193) NIHSS ≥ 8 (N = 1423) P Value
Successful reperfusion 83.4% (161/193) 82.2% (1169/1422) 0.690
TICI3 47.7% (92/193) 44.4% (633/1422) 0.441
Number of maneuvers (N = 1147) 1 (IQR 1–2, N = 158) 2 (IQR 1–3, N = 984) 0.129
Time from groin puncture to reperfusion (min, N=1507) 42 (IQR 29–65, N = 184) 47 (IQR 30–78, N = 1323)   0.075
Other devices used as rescue (N = 1338) 8.5% (14/164) 12.1% (142/1169) 0.196
Complications 11.4% (23/193) 12.6% (179/1420) 0.818
Type of complications (relative frequency)
 Vasospasms 30.4% (7/23) 24.7% (44/178)
 Dissection 34.8% (8/23) 16.9% (30/178)
 Perforation 13.0% (3/23) 11.8% (21/178)
 Other 13.0% (3/23) 14.6% (26/178)
 ENT 8.7% (2/23) 30.9% (55/178)
 Multiple 0% (0/23) 1.1% (2/178)
 Missing information on type of complication – N = 1
sICH 4.2% (8/192) 6.0% (85/1417) 0.409
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alone [34]. These findings were corroborated by a recent 
meta-analysis suggesting improved outcome in patients 
with NIHSS ≤ 8 if treated with thrombectomy as opposed 
to best medical treatment [41]. However, in this analysis, 
increased rates of sICH after endovascular therapy were 
found, warranting further data [41]. Importantly, in the 
presented cohort, the rates of sICH were markedly lower 
(4.2%) than the proportion of patients experiencing sICH 
described in the meta-analysis (13.6%) [41].
In line with our findings, several other single-arm EVT 
studies also found high rates of procedural success and good 
safety profiles of EVT in patients presenting with LVO and 
minor symptoms [18, 19, 42–44]. Corroborating our obser-
vations regarding the beneficial effect of successful reperfu-
sion, Dargazanli et al. also reported that patients in whom 
TICI2b or TICI3 could be achieved do significantly better, 
although uncertainty of point estimates was relatively large 
[18]. In addition to these results, we found no evidence that 
the effect of achieving successful reperfusion is different in 
patients treated with IVT and those with contraindication 
for IVT. While the presented data is insufficient to answer 
the questions regarding preferred treatment regimens in the 
subgroup of patients presenting with low NIHSS, the data 
suggest that routine EVT in this subgroup of patients may be 
beneficial, because it is very likely that successful and timely 
reperfusion will be achieved more often.
The rate of complications in patients with NIHSS < 8 was 
comparable to recent meta-analysis data [20] and matches 
the frequency of complications observed in patients present-
ing with NIHSS ≥ 8 in this registry. Two-thirds of complica-
tions were comprised by iatrogenic cervical dissections and 
periprocedural vasospasms, both associated with relatively 
low risk of prompting unfavorable outcomes [21]. When 
adjusting for the lower rates of successful reperfusion in 
patients with procedural complications, we did not observe 
an independent effect of complications on outcome (data not 
shown). This suggests that not achieving successful reperfu-
sion, rather than the complication itself puts patients at risk 
for poor outcomes. Moreover, some reassurance is provided 
that the rates of non-hemorrhagic neurological worsening 
are unlikely to be higher than if treated with IVT only. In 
a recent analysis of the SITS registry dealing with minor 
strokes treated with IVT, non-hemorrhagic neurological 
worsening was found in 30% of ICA-T or Tandem occlu-
sions, 16.7% of other ICA occlusion, 9.3% of M1 and 5.8% 
of M2 occlusions [8]. Transferring those frequencies to our 
study population with available 24 h NIHSS, a rate of 11.9% 
could be expected (Supplementary Table III), which is non-
significantly less frequent than what we have observed in our 
cohort (13.8%). It has to be kept in mind though, that early 
responders to IVT (unlikely to experience non-hemorrhagic 
neurological worsening) are a priori excluded in our cohort. 
Although the numbers were generally small, it should be 
stressed that more than every third patient with persistent 
occlusion on angiography in whom no successful reperfu-
sion could be achieved experienced non-hemorrhagic neuro-
logical worsening in our cohort (38.1%, 8/21). Nevertheless, 
it seems obvious that subjecting all patients with NIHSS < 8 
to EVT as a clinical routine will unavoidably put a minor-
ity of patients at risk for worsening of the perfusion status 
as compared to when endovascular treatment would have 
been withheld and our observation that non-hemorrhagic 
neurological worsening occurs more often in patients with 
low NIHSS supports this. Hence, it will need a randomized 
controlled trial to clarify if the potential benefits of prevent-
ing natural course deterioration outweighs the risks associ-
ated with procedural complications in patients who would 
otherwise stay clinically stable. Such a trial may also incor-
porate imaging selection criteria to identify patients with 
mild symptoms most likely to benefit [45]. In summary, the 
data presented stress that the effect of achieving success-
ful reperfusion in the subgroup of patients with low NIHSS 
seems substantial and the comparable frequency of non-
hemorrhagic neurological worsening between our cohort 
and findings derived from minor strokes patients included 
in the SITS registry further points towards safety equipoise 
in this subgroup of patients.
Limitations
This is a single-arm multicenter retrospective registry and 
has associated limitations. No comparison to patients treated 
with medical management only was performed. Several 
factors including final mTICI score and initial ASPECTS 
were not core-lab adjudicated but were rated at the respec-
tive centers. Subgroup analyses were generally confined to 
small cohorts, which introduces a large uncertainty of the 
presented effects as indicated by relatively wide confidence 
intervals. Moreover, interaction analyses may be underpow-
ered. The available sample represents minor strokes with 
LVO in whom the exact reasons for this treatment decisions 
are not known and may thus do not present the whole popu-
lation of minor strokes with LVO. Importantly, patients who 
reperfused before endovascular treatment were excluded 
from the registry. Hence, interaction analysis or comparisons 
of e.g. bridging vs direct mechanical thrombectomy patients 
will only cover patients, who had persistent occlusions on 
the first angiography run, or did not clinically improve after 
IVT, respectively. The lack of a significant difference or 
interaction thus does not imply that pre-interventional IVT 
is not beneficial in this subcohort of patients, because at 
least 10%–20% of patients will reperfuse before endovascu-
lar thrombectomy [46, 47], which has been associated with 
better clinical outcomes.
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Conclusion
Achieving successful reperfusion in patients with persistent 
LVO on first angiography runs is beneficial in patients pre-
senting with NIHSS < 8 and this effect is independent of 
whether patients were pretreated with IVT or not. Given the 
differences of the likelihood to achieve timely and complete 
reperfusion between best medical management and EVT, the 
presented data may be interpreted as a hint towards poten-
tial benefits of emergent routine EVT in this subgroup of 
patients. Randomized controlled trials comparing best medi-
cal treatment vs EVT in LVO patients with minor symptoms 
are warranted.
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